Inquiry Basket
Loading ......
Egg Drop Syndrome (EDS) is a significant viral disease affecting laying hens, characterized by a sudden drop in egg production and the laying of soft-shelled or shell-less eggs. Caused by the Egg Drop Syndrome virus (EDSV), an adenovirus, this condition has posed substantial economic challenges to the poultry industry since its emergence. The development and widespread use of inactivated vaccines have proven to be the most effective strategy for controlling EDS, safeguarding flock productivity, and ensuring the economic viability of layer and breeder operations worldwide.
Figure 1. Mechanisms of Inactivated Egg Drop Syndrome Virus (EDSV) Action.
Egg Drop Syndrome virus is an atypical avian adenovirus, classified within the genus Atadenovirus. Unlike many other avian adenoviruses, EDSV is unique in its origin and pathogenesis. Genetic and antigenic studies have revealed that the virus is closely related to the duck adenovirus 1, leading to the widely accepted hypothesis that EDSV originated as a duck virus that later adapted to infect chickens. This cross-species jump is believed to have occurred relatively recently in evolutionary terms, explaining the high susceptibility of chicken flocks to a pathogen that likely evolved in a different host species. The virus itself is non-enveloped, with an icosahedral capsid structure typical of adenoviruses. Its genome consists of linear double-stranded DNA, making it more genetically stable than RNA viruses. This stability has important implications for vaccine development, as the virus does not rapidly mutate or generate immune-evasive variants. EDSV is capable of agglutinating red blood cells from chickens, ducks, and several other species—a property known as hemagglutination, which forms the basis for important diagnostic tests used to monitor flock health and vaccine efficacy.
EDSV is a non-enveloped, icosahedral virus with a diameter of approximately 70-90 nanometers, distinguished by its double-stranded DNA genome. The viral genome is approximately 33-35 kilobases in length, encoding a range of structural and non-structural proteins that are essential for viral replication, assembly, and pathogenicity. The structural proteins include the hexon, penton base, and fiber proteins, which form the viral capsid and play critical roles in viral attachment to host cell receptors and entry into host cells. EDSV primarily infects poultry species, with laying hens being the most susceptible, especially those in their peak laying period. The virus targets the reproductive tract of hens, including the ovary and oviduct, as well as the respiratory tract, which serves as a primary route of entry. Upon infection, EDSV replicates in epithelial cells of the oviduct, leading to damage of the mucosal lining and impaired egg formation. This damage results in the production of soft-shelled, shell-less, or misshapen eggs, along with a significant drop in egg production—often by 30-50% or more in severe cases.
Inactivated EDSV vaccines work by stimulating the host's adaptive immune system to produce specific antibodies against EDSV antigens, primarily the hexon and fiber proteins. When a vaccinated bird is exposed to live EDSV, these pre-formed antibodies bind to the viral particles, neutralizing their ability to attach to and enter host cells, thereby preventing infection or reducing the severity of disease. Upon administration, the inactivated EDSV antigens are taken up by antigen-presenting cells (APCs) such as macrophages and dendritic cells, which process and present the antigens to T lymphocytes. This activation of T cells triggers the differentiation of B lymphocytes into plasma cells, which produce specific IgG and IgA antibodies against EDSV. IgG antibodies circulate in the bloodstream, providing systemic protection, while IgA antibodies are secreted onto mucosal surfaces (such as the respiratory and reproductive tracts), preventing viral entry at the point of infection.
Inactivated EDSV vaccines are widely used in commercial poultry production, particularly in laying hen flocks, to prevent EDSV outbreaks and minimize economic losses. The vaccination schedule typically involves administering two doses of the vaccine to pullets (young female chickens) before they reach sexual maturity and start laying eggs. The first dose is usually given at 14-16 weeks of age, with a booster dose 4-6 weeks later, shortly before the onset of lay. This timing ensures that birds develop a strong immune response before they are most susceptible to EDSV infection. The efficacy of inactivated EDSV vaccines is generally high, with properly vaccinated flocks showing a significant reduction in EDSV-related morbidity and mortality. Vaccinated birds exhibit higher egg production rates, fewer abnormal eggs, and lower viral shedding compared to unvaccinated birds. In addition, vaccination helps to reduce the spread of EDSV within and between flocks, contributing to overall disease control in the poultry industry.
Inactivated Egg Drop Syndrome virus vaccine represents a triumph of applied virology and veterinary preventive medicine. By providing safe, effective, and durable protection against a pathogen that once caused devastating economic losses, this vaccine has become an indispensable tool for poultry producers worldwide. Understanding the virus, the disease it causes, and the science behind the vaccine enables informed decisions about vaccination programs that protect flock productivity and profitability. As with all aspects of poultry health management, success depends on attention to detail—proper vaccine selection, correct storage and handling, accurate administration, and ongoing monitoring of results. When these elements align, inactivated EDS vaccine delivers on its promise of healthy, productive flocks and sustainable poultry production.
| Target | Cat. No. | Product Name | Host | |
| EDSV | DAGF-106 | Inactivated Egg drop syndrome virus antigen | Chicken | Inquiry |
Loading ......
